Indications
Romvimza is indicated for treatment of adult patients with symptomatic tenosynovial giant cell tumour (TGCT) associated with clinically relevant physical function deterioration and in whom surgical options have been exhausted or would induce unacceptable morbidity or disability.
Composition
- Active substance
- vimseltinib dihydrate
- International name (INN)
- vimseltinib
Official product information
The European public assessment report holds the summary of product characteristics and the package leaflet in every EU language.
Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.
At a glance
- Medicine
- Romvimza
- Active substance
- vimseltinib dihydrate
- ATC code
- L01EX
- Therapeutic area
- Giant Cell Tumor of Tendon Sheath